AI Will Build Totally New Drugs by 2031 | Sam Rodriques
MTS
October 31, 2026
Edison Scientific founder and CEO Sam Rodriques breaks down their new partnership with Pfizer to deploy superintelligence across pharma R&D.
Sam Rodriques
The first thing that's gonna happen is that we're gonna learn how to use existing drugs for more indications, right? For more different diseases. And over the course of the next year or two, I think we're gonna have way more cures because of that kind of repurposing. Wow. And then after that, you know, on the kind of three to five year time scale, we'll start to get even like totally new drugs, right? Not repurposed, but totally new drugs that come out that are kind of fully AI driven.
SPEAKER_2
Hello everyone, welcome back to MTS. We are joined today with Sam Rodriques, who is the founder and CEO of Edison Scientific, which has just announced their partnership with Pfizer to bring super intelligence to their research and development organization. So Sam, welcome to MTS.
Sam Rodriques
Yes, thank you for having me. Great to be here.
SPEAKER_2
Thank you so much for coming. We were just talking right before we went live, how important it is to highlight some of the latest things happening when it comes to AI, science, curing diseases. What does this partnership mean?
Sam Rodriques
The partnership is basically an attempt by Pfizer to figure out how to bring superintelligence into research and into development. So I think it's very obvious at this point, AI and superintelligence are going to completely change the way that we discover new medicine, and that we bring that medicine to patients. And it's just critical for the drug developers to figure out how to do that. And so we have been around now for a while, developing agents and models and so on, for science and for drug discovery.
And we're now have been announcing our first couple of partnerships in this area.
SPEAKER_2
This is amazing. So now let's get into some specific reasons and examples of what this actually means for the day-to-day person. I know right before we went live, you were sharing some emails that you're actually receiving from parents and past patients. Tell me a little bit more about that.
Sam Rodriques
Yeah, absolutely. So we work with a number of physicians who work on genetic medicine. One of the ones who we work with a lot, his name is Fyodor Arnav. And when you're working on genetic medicine, you get emails often from the parents of children who suffer from genetic diseases. So we saw on the other day about a child who's 20 months old, who has a genetic mutant, which means that they are progressively going blind and deaf. And things like that, this happens all around the world all the time, and it's obviously heartbreaking. And we are living in an era, we are coming into the era of AI and the era of superintelligence, and this should not be happening anymore. I mean, the potential for AI to just transform the way the medicine works and to mean that we can get cures to all of those children and all patients of all diseases around the world is so high. But there's a huge infrastructural gap. There's a huge gap at actually deploying the AI in order to, into doctor's practices, into the actual process of discovering new medicines, into the regulators to speed up the entire process. And so that's really what we're focused on. I mean, what I tell people is, what we're really focused on is figuring out, how do you bring super intelligence to medicine? Super intelligence is here or very nearly here. But how do we make sure that we're actually going to reap the benefits?
That's the thing that we have been really focused on.
SPEAKER_2
And this is a big reason I wanted to talk to you particularly. I think right now within a 10-block radius of our offices, we have all of this intelligence that's almost trapped within these models, but actually getting it diffused into society, diffused and felt impact across the world is a whole other box of worms. And so tell me a little bit, you say this can help scientists, this can help doctors, this can help regulators. How exactly does this work?
Sam Rodriques
So the critical thing to understand is that in science, the bottleneck is data. So there are several bottlenecks. One bottleneck is intelligence. Well, that bottleneck is going out the door because now we have abundant intelligence. Another bottleneck is data. Another bottleneck is the ability to conduct experiments, which basically boils down to physical laboratory equipment and supply chains and things like that. The existing companies, these big pharma companies like Pfizer, like Eli Lilly, like AstraZeneca, all these companies, they have the infrastructure that you need to discover and develop drugs. Now we have the kind of intelligence, we have the AI, we have the language models. And the challenge is to figure out how to bring that in and hook it up to the data, hook it up to the supply chains in a way, hook it up to the experiments in a way that actually allows those companies to make the most use of their data.
Read the other 10 minutes of this episode here.
$15 gets you this episode and 99 more. Credits never expire. After checkout, one link brings you back here to read it.
Not what you expected? Full refund within 14 days.
Thousands of transcripts fetched by people building searchable podcast archives
Fetch transcripts with code
The same credits work from a script or an AI agent. The demo key returns a sample episode in full, no card needed:
curl -H "x-api-key: pt_demo" \
https://spoken.md/transcripts/1000651996090Markdown with the speakers named, for your notes, your knowledge base, or anything that makes HTTP calls.
From $0.10 per transcript. No subscription. Credits never expire. Prices exclude VAT, added at checkout for EU customers. Not what you expected? Email us within 14 days with 20 or fewer credits used and we refund the pack in full.
Using your own key:
curl -H "x-api-key: YOUR_KEY" \
https://spoken.md/transcripts/1000799120161